Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-10-22 / BMC Cancer 2010 Oct;10:578Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-05-01 / J. Immunother. 2010 May;33(4):425-34Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate
/in Hypernephroma, International Publications /von 2009-11-01 / Scand. J. Immunol. 2009 Nov;70(5):481-9Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81Vaccination strategies in patients with renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses
/in Hypernephroma, International Publications /von 2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-97Vaccine therapy in patients with renal cell carcinoma
/in Hypernephroma, International Publications, IOZK Veröffentlichungen /von 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
/in Hypernephroma, International Publications /von 2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-41Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
/in Hypernephroma, International Publications /von 2008-10-01 / J. Immunother. 2008 Oct;31(8):771-80IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de